Chlorotoxin bound magnetic nanovector tailored for cancer cell targeting, imaging, and siRNA delivery

Veiseh, Omid; Kievit, Forrest M.; Chen, Fang; Mu, Ni; Jana, Soumen; Leung, Matthew; Mok, Hyejung; Ellenbogen, Richard G.; Park, James O.; Zhang, Miqin

doi:10.1016/j.biomaterials.2010.07.016

Cited by 169 publications

(121 citation statements)

References 37 publications

Supporting

Mentioning

119

Contrasting

Order By: Relevance

“…The hydrodynamic size and z potential of iron oxide NPs functionalized with chlorotoxin 185 and changes in the hydrodynamic size and surface charge upon assembling cRGD functionalized iron oxide NPs 196 were reported. Preferred binding of cRGD functionalized over non-functionalized iron oxide NPs towards cancer cells was shown in in vitro studies.…”

mentioning

confidence: 99%

See 1 more Smart Citation

Stabilization and functionalization of iron oxide nanoparticles for biomedical applications

2011

View full text Add to dashboard Cite

Superparamagnetic iron oxide nanoparticles (NPs) are used in a rapidly expanding number of research and practical applications in the biomedical field, including magnetic cell labeling separation and tracking, for therapeutic purposes in hyperthermia and drug delivery, and for diagnostic purposes, e.g., as contrast agents for magnetic resonance imaging. These applications require good NP stability at physiological conditions, close control over NP size and controlled surface presentation of functionalities. This review is focused on different aspects of the stability of superparamagnetic iron oxide NPs, from its practical definition to its implementation by molecular design of the dispersant shell around the iron oxide core and further on to its influence on the magnetic properties of the superparamagnetic iron oxide NPs. Special attention is given to the selection of molecular anchors for the dispersant shell, because of their importance to ensure colloidal and functional stability of sterically stabilized superparamagnetic iron oxide NPs. We further detail how dispersants have been optimized to gain close control over iron oxide NP stability, size and functionalities by independently considering the influences of anchors and the attached sterically repulsive polymer brushes. A critical evaluation of different strategies to stabilize and functionalize core-shell superparamagnetic iron oxide NPs as well as a brief introduction to characterization methods to compare those strategies is given.

show abstract

mentioning

confidence: 99%

“…Ligands, such as antibodies and peptides, are often comparable in size to the iron oxide NPs 185 and their coupling can significantly change the hydrodynamic size (Fig. 11).…”

mentioning

confidence: 99%

Stabilization and functionalization of iron oxide nanoparticles for biomedical applications

2011

View full text Add to dashboard Cite

show abstract

“…Superparamagnetic iron oxide nanoparticles (SPIONs) are another example of siRNA-magnetic carriers, which are also widely studied MR contrast agents useful in both imaging and drug delivery applications [56][57][58]. The large surface area of SPIONs makes them perfect candidates for functional modification, enabling the conjugation of targeting molecules, drugs, and imaging contrasts agents.…”

Section: Magnetic Nanoparticles For Rnaimentioning

confidence: 99%

“…It has also been studied the influence of nature and length of the chains between the succinimydil group and the maleimide [119]. Following with the formation of non-labile bonds, the linker SIA (Succinimidyl iodoacetate) that has a N-hydroxisuccinimidyl ester and a iodoacetyl group, is interesting once it introduces less atoms in the final structure than others [56,73]. …”

Section: Covalent Approachmentioning

confidence: 99%

15 years on siRNA delivery: Beyond the State-of-the-Art on inorganic nanoparticles for RNAi therapeutics

et al. 2015

View full text Add to dashboard Cite

RNAi has always captivated scientists due to its tremendous power to modulate the phenotype of living organisms. This natural and powerful biological mechanism can now be harnessed to downregulate specific gene expression in diseased cells; opening up endless opportunities. Since most of the conventional siRNA delivery methods are limited by a narrow therapeutic index and significant side and off-target effects, we are now in the dawn of a new age in gene therapy driven by nanotechnology vehicles for RNAi therapeutics. Here, we outlook the "do's and dont's" of the 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 61 62 63 64 65 REVIEW NANO TODAY 2 inorganic RNAi nanomaterials developed in the last 15 years and the different strategies employed are compared and scrutinized, offering important suggestions for the next 15. *Manuscript Click here to view linked References

show abstract

“…O6-benzylguanine and siRNA) to glioma cells. [120][121][122] Other toxins such as BLZ-100 are being investigated. [123,124] …”

Section: Solid Lipid Nanoparticlesmentioning

confidence: 99%

Tailored nanocarriers and bioconjugates for combating glioblastoma and other brain tumors

ElAmrawy¹,

Othman²,

Adkins³

et al. 2016

JCMT

View full text Add to dashboard Cite

Worldwide, the incidence of primary brain tumors is on the rise. Unfortunately, noninvasive drug therapy is hampered by poor access of most drugs to the brain due to the insurmountable blood-brain barrier (BBB). Nanotechnology holds great promise for noninvasive therapy of severe brain diseases. Furthermore, recent bioconjugation strategies have enabled the invasion of the BBB via tailored-designed bioconjugates either with targeting moieties or alterations in the physicochemical and/or the pharmacokinetic parameters of central nervous system (CNS) active pharmaceutical ingredients. Multifunctional systems and new entities are being developed to target brain cells and tumor cells to resist the progression of brain tumors. Direct conjugation of an FDA-approved drug with a targeting moiety, diagnostic moiety, or pharmacokinetic-modifying moiety represents another current approach in combating brain tumors and metastases. Finally, genetic engineering, stem cells, and vaccinations are innovative nontraditional approaches described in different patents for the management of brain tumors and metastases. This review summarizes the recent technologies and patent applications in the past five years for the noninvasive treatment of glioblastoma and other brain tumors. Till now, there has been no optimal strategy to deliver therapeutic agents to the CNS for the treatment of brain tumors and metastases. Intensive research efforts are ongoing to bring novel CNS delivery systems to potential clinical application.

show abstract

Chlorotoxin bound magnetic nanovector tailored for cancer cell targeting, imaging, and siRNA delivery

Cited by 169 publications

References 37 publications

Stabilization and functionalization of iron oxide nanoparticles for biomedical applications

Stabilization and functionalization of iron oxide nanoparticles for biomedical applications

15 years on siRNA delivery: Beyond the State-of-the-Art on inorganic nanoparticles for RNAi therapeutics

Tailored nanocarriers and bioconjugates for combating glioblastoma and other brain tumors

Contact Info

Product

Resources

About